In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.
Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.
New membership rules by PhRMA governing R&D spending come as the industry tries to change its image as profiteers of sickness and disease.
A study from Yale researchers finds that about a third of new drugs, especially ones with accelerated approval, have safety issues, NPR reports.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.
The company is recruiting patients with TRK fusions and different cancer types in a Phase II basket trial that may pave the way for a "molecular label" for its drug.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.